Elevation of Serum Ferritin is Associated with the Outcome of Patients with Newly Diagnosed Multiple Myeloma.
10.3904/kjim.2009.24.4.368
- Author:
Moo Kon SONG
1
;
Joo Seop CHUNG
;
Young Mi SEOL
;
Ho Jin SHIN
;
Young Jin CHOI
;
Goon Jae CHO
Author Information
1. Department of Hematology-Oncology, Pusan National University Hospital, Busan, Korea. hemon@pusan.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Ferritin;
Multiple myeloma;
Survival
- MeSH:
Adult;
Aged;
Aged, 80 and over;
C-Reactive Protein/analysis;
Female;
Ferritins/*blood;
Humans;
Male;
Middle Aged;
Multiple Myeloma/*blood;
Prognosis;
Proportional Hazards Models;
beta 2-Microglobulin/blood
- From:The Korean Journal of Internal Medicine
2009;24(4):368-373
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Serum ferritin is a marker of acute phase reactions and iron storage. In addition, hematologic malignancies are associated with elevated serum ferritin levels. Other studies have suggested that ferritin is a surrogate for advanced disease and has an impact on relapse, because elevated serum ferritin predicts overall survival (OS) and relapse-free survival following autologous stem cell transplantation for lymphomas. METHODS: We studied 89 consecutive patients with newly diagnosed multiple myeloma to determine the value of serum ferritin in comparison with known prognostic factors. RESULTS: The OS in the elevated serum ferritin group (> or =300 ng/mL) was shorter than that in the normal serum ferritin group (<300 ng/mL, p<0.001) after a median follow-up of 25 months. In univariate analysis, elevated ferritin was correlated with poor survival in the patients (relative risk [RR], 2.588; 95% confidence interval [CI], 1.536 to 4.358; p<0.001). Furthermore, multivariate analysis showed that elevated serum ferritin was an independent predictor of mortality in patients with multiple myeloma (RR, 2.594; 95% CI, 1.403 to 4.797; p=0.002). CONCLUSIONS: The serum ferritin can a prognostic parameter of survival as well as disease activity in patients with multiple myeloma.
